Premier Path Wealth Partners, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Premier Path Wealth Partners, LLC
- $634 Billion
- Q3 2024
A detailed history of Premier Path Wealth Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Premier Path Wealth Partners, LLC holds 625 shares of REGN stock, worth $445,250. This represents 0.1% of its overall portfolio holdings.
Number of Shares
625
Previous 620
0.81%
Holding current value
$445,250
Previous $651 Million
0.83%
% of portfolio
0.1%
Previous 0.11%
Shares
4 transactions
Others Institutions Holding REGN
# of Institutions
1,534Shares Held
83.6MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.64 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.02 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.34 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.49 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.06 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $76.4B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...